Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Phase I/II study of single agent ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL)

Date

08 Oct 2016

Session

CNS tumours

Presenters

Christian Grommes

Citation

Annals of Oncology (2016) 27 (6): 103-113. 10.1093/annonc/mdw367

Authors

C. Grommes, I. Gavrilovic, T. Kaley, C. Nolan, A. Omuro, J. Wolfe, E. Pentsova, V. Hatzoglou, I.K. Mellinghoff, L. Deangelis

Author affiliations

  • Neurology, Memorial Sloan Kettering Cancer Center, 10065 - New York/US
More

Resources

Background

PCNSL is an aggressive primary brain tumor. Outcome and treatment options are poor for recurrent/refractory (r/r) disease. Response rates (ORR) range between 30-60% with a progression free survival (PFS) of 2-5 months. Ibrutinib has shown promising clinical response in some B-cell malignancies. This trial investigates Ibrutinib in patients with r/r PCNSL and SCNSL.

Methods

Eligible patients had r/r PCNSL or SCNSL, age ≥ 18, ECOG ≤ 2, normal end-organ function, and unrestricted number of CNS directed prior therapies. In patients with SCNSL disease, systemic disease needed to be absent.

Results

Twenty patients were enrolled (3 at 560 mg; 17 at 840 mg). Median age was 69 (range 21-85); 12 were women. Median ECOG was 1 (0: 2, 1: 12, 2: 6). 65% had PCNSL and 35% SCNSL; 70% had recurrent disease. Eleven had parenchymal disease, 3 isolated cerebrospinal fluid (CSF) involvement and 6 both. The median prior CNS directed therapy was 2; all methotrexate regimens. Despite clinical and radiographic response, 2 patients withdrew and 1 stopped due to toxicity (fungal infection). Four grade 4 toxicities were observed in 4 patients (lymphopenia (2), sepsis (1), neutropenia (1)). Ten patients developed grade 3 toxicities, including lymphopenia in 3 patients, thrombocytopenia in 2, hyperglycemia in 2, lung infection in 2, neutropenia in 1, urinary tract infection in 1, colitis in 1, and fungal encephalitis in 1. The most common toxicities were hyperglycemia, anemia, and thrombocytopenia. After a median follow-up of 147 days, 16/20 patients were evaluated for response: 4 CR (3 in CSF; 1 in the parenchyma), 9 PR, and 3 PD; 65% (13/20) ORR. In 3 patients response has not been confirmed in a 2nd assessment. The median PFS is 5.5 months (longest: 13.2 months). The mean Ibrutinib concentration in the CSF at day 1 and 29 was 1.75 ng/mL (3.97 nM) and 2.51 ng/mL (5.6 nM). The CSF Ibrutinib concentrations reached in patients is above the IC50 (1nM) required in vitro to reduce growth of lymphoma cells. Molecular testing is in process to associate genomic alterations and outcome.

Conclusions

Patients with CNS lymphoma tolerate Ibrutinib with manageable toxicities. Ibrutinib might be a therapeutic alternative that should be further investigated in r/r CNS lymphoma patients.

Clinical trial identification

NCT02315326

Legal entity responsible for the study

Memorial Sloan Kettering Cancer Center

Funding

Pharmacyclics

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings